# DiaCarta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diacarta-2

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.effiebigdata.com
- Total disclosed funding: $53M
- Latest round: Series B (Nov 20, 2017)
- Investors on record: 3

## About

Established in 2016 and based in Nanjing, China, DiaCarta China operates as a molecular diagnostic technology developer that mainly provides molecular diagnostic services. It has branches and third-party inspection center qualifications in Shanghai, Tianjin, Taizhou and Hangzhou, and we also have branches in the United States. In November 2017, the company raised CNY 300 million in series B funding from lead and new investorFerrer, Freeman & Co and new investor GHC.

The company mainly provides molecular diagnostic services. It has four technology platforms, which are XNA®, isobDNA™, DigiPlex™, and high-throughput sequencing experimental platform. Products and services include ColoScape® for early screening of colorectal cancer, genetic testing for chemotherapy drugs, RadTox™ for radiotherapy monitoring, and 21-gene testing for breast cancer.

The company generates revenue by providing molecular diagnostic services such as ColoScape® for early screening of colorectal cancer and genetic testing for chemotherapy drugs.

## Funding rounds

- Series B, Nov 20, 2017, $45M — Ferrer, Freeman & Co, GHC
- Series A, Jan 9, 2015, $8M — BioVeda Capital

## Investors

- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series A
- Ferrer, Freeman & Co (https://capitalatlas.ai/funds/ferrer-freeman-co) — Series B
- GHC — Series B